MRK - Merck & Co Inc Stock Price, Fair Value and News

125.03USD-0.34 (-0.27%)Delayed as of 18 Apr 2024, 02:48 pm ET

Market Summary

USD125.03-0.34

Delayedas of 18 Apr 2024, 02:48 pm

-0.27%

MRK Stock Price

View Fullscreen

MRK RSI Chart

MRK Valuation

Market Cap

317.6B

Price/Earnings (Trailing)

870.05

Price/Sales (Trailing)

5.28

EV/EBITDA

93.93

Price/Free Cashflow

34.73

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

3.14%

Return on Equity

0.97%

Return on Assets

0.34%

Free Cashflow Yield

2.88%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

60.1B

Rev. Growth (Yr)

5.79%

Rev. Growth (Qtr)

-8.34%

MRK Earnings

Earnings (TTM)

365.0M

Earnings Growth (Yr)

-140.64%

Earnings Growth (Qtr)

-125.84%

Breaking Down MRK Revenue

52 Week Range

101.35125.45

(Low)(High)

Last 7 days

-1.1%

Last 30 days

3.3%

Last 90 days

5.8%

Trailing 12 Months

9.2%

How does MRK drawdown profile look like?

MRK Financial Health

Current Ratio

1.25

Debt/Equity

0.9

Debt/Cashflow

0.39

MRK Investor Care

Dividend Yield

2.36%

Dividend/Share (TTM)

2.96

Buy Backs (1Y)

0.23%

Diluted EPS (TTM)

0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	57.9B	58.3B	59.3B	60.1B
2022	54.0B	57.2B	59.0B	59.3B
2021	41.0B	43.0B	45.2B	48.7B
2020	40.4B	38.0B	36.5B	42.4B
2019	43.1B	44.4B	46.0B	39.1B
2018	40.7B	41.3B	41.7B	42.3B
2017	39.9B	40.0B	39.8B	40.1B
2016	39.4B	39.4B	39.9B	39.8B
2015	41.4B	40.2B	39.8B	39.5B
2014	43.6B	43.5B	43.1B	42.2B
2013	46.2B	44.9B	44.5B	44.0B
2012	48.2B	48.4B	47.8B	47.3B
2011	46.1B	47.0B	47.8B	48.0B
2010	33.5B	38.9B	44.0B	46.0B
2009	24.6B	25.6B	27.0B	27.4B
2008	0	24.1B	24.0B	23.9B
2007	0	0	0	24.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Merck & Co Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 14, 2024	davis robert m	sold	-10,661,600	125	-85,021	chairman, ceo & president
Feb 14, 2024	davis robert m	acquired	6,268,600	73.73	85,021	chairman, ceo & president
Feb 14, 2024	litchfield caroline	acquired	2,223,940	58.08	38,291	evp & cfo
Feb 14, 2024	litchfield caroline	sold	-4,805,520	125	-38,291	evp & cfo
Feb 13, 2024	romanelli joseph	sold	-124,888	124	-1,000	president, human health int?l
Feb 13, 2024	davis robert m	sold	-18,877,400	125	-150,000	chairman, ceo & president
Feb 13, 2024	davis robert m	acquired	11,127,200	74.1811	150,000	chairman, ceo & president
Feb 09, 2024	li dean y	acquired	912,553	62.07	14,702	executive vp & president, mrl
Feb 09, 2024	li dean y	sold	-1,845,080	125	-14,702	executive vp & president, mrl
Feb 07, 2024	williams david michael	sold	-185,108	127	-1,451	evp,chief info&digital officer

Which funds bought or sold MRK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Pinnacle Bancorp, Inc.	added	4.16	174,982	846,327	0.25%
Apr 16, 2024	Addenda Capital Inc.	reduced	-0.28	1,306,280	7,663,230	0.29%
Apr 16, 2024	SCHARF INVESTMENTS, LLC	added	7.16	291,691	1,274,140	0.04%
Apr 16, 2024	FLAGSHIP HARBOR ADVISORS, LLC	added	0.18	940,755	5,366,710	0.34%
Apr 16, 2024	New England Research & Management, Inc.	added	3.1	414,000	2,085,000	1.02%
Apr 16, 2024	First Dallas Securities Inc.	added	10.83	691,000	2,713,000	1.25%
Apr 16, 2024	AMF Tjanstepension AB	added	3.67	19,435,500	95,968,100	0.73%
Apr 16, 2024	Stratos Wealth Advisors, LLC	reduced	-63.39	-3,748,880	2,983,540	0.18%
Apr 16, 2024	Cypress Wealth Services, LLC	added	58.56	214,736	448,366	0.10%
Apr 16, 2024	Tarbox Family Office, Inc.	added	40.65	222,270	538,768	0.10%

Are Funds Buying or Selling MRK?

Are funds buying MRK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRK

No. of Funds

Unveiling Merck & Co Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.66%	244,767,034	SC 13G/A
Jan 26, 2024	blackrock inc.	8.0%	201,836,434	SC 13G/A
Feb 09, 2023	vanguard group inc	8.96%	227,205,978	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	215,011,385	SC 13G/A
Feb 09, 2022	vanguard group inc	8.36%	211,202,531	SC 13G/A
Feb 01, 2022	blackrock inc.	7.8%	198,224,264	SC 13G/A
Feb 10, 2021	vanguard group inc	8.24%	208,410,644	SC 13G/A
Feb 05, 2021	blackrock inc.	7.8%	196,213,804	SC 13G/A
Feb 12, 2020	vanguard group inc	8.26%	210,542,333	SC 13G/A
Feb 05, 2020	blackrock inc.	7.5%	190,783,225	SC 13G/A

Recent SEC filings of Merck & Co Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	10-K/A	Annual Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 08, 2024	3	Insider Trading
Apr 01, 2024	PX14A6G	PX14A6G
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading

Peers (Alternatives to Merck & Co Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.8B	85.2B	-7.62%	-10.06%	9.92	4.1	6.46%	95.94%
MRK	317.6B	60.1B	3.25%	9.20%	870.05	5.28	1.40%	-97.49%
PFE	143.5B	46.5B	-8.33%	-37.34%	-103.34	3.08	42.59%	-114.62%
AMGN	141.5B	28.2B	-2.53%	7.29%	21.07	5.02	7.09%	2.52%
GILD	83.4B	27.1B	-8.60%	-20.08%	14.73	3.08	-0.60%	23.36%
TEVA	14.8B	15.8B	-0.90%	54.57%	-25.67	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	0.13%	-17.24%	-320.54	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-12.75%	-17.88%	11.28	2.41	49.61%	324.78%
BHC	3.2B	8.8B	-7.68%	16.09%	-5.35	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-6.53%	-6.23%	14	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-10.42%	-30.36%	-3.78	1.79	24.65%	80.36%
TXMD	21.8M	1.3M	-17.83%	-48.08%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	-12.17%	23.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-33.93%	-94.71%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Merck & Co Inc News

Latest updates

Merck & Co Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-8.3%	14,631	15,962	15,035	14,487	13,830	14,959	14,593	15,901	13,521	13,154	11,402	10,627	10,064	10,929	9,353	12,057	4,149	12,397	11,760	10,816	10,998
S&GA Expenses	11.3%	2,804	2,519	2,702	2,479	2,687	2,520	2,512	2,323	2,830	2,336	2,281	2,187	2,437	2,060	2,085	2,555	1,729	2,589	2,712	2,425	2,643
R&D Expenses	191.1%	9,627	3,307	13,321	4,276	3,775	4,399	2,798	2,576	3,068	2,445	4,321	2,412	5,771	3,349	2,085	2,209	2,400	3,204	2,189	1,931	2,214
EBITDA Margin	-60.5%	0.06*	0.15*	0.12*	0.29*	0.31*	0.32*	0.35*	0.32*	0.32*	0.19*	0.14*	0.17*	-	-	-	-	-	-	-	-	-
Income Taxes	-194.3%	-820	870	637	825	496	330	538	554	85.00	695	503	238	7.00	380	396	619	306	440	615	205	827
Earnings Before Taxes	-136.4%	-2,046	5,620	-5,335	3,650	3,513	3,583	4,487	4,861	3,909	5,266	1,717	2,987	-2,983	2,706	2,741	3,838	-1,502	2,347	3,259	3,067	2,605
EBT Margin	-75.0%	0.03*	0.13*	0.09*	0.26*	0.28*	0.29*	0.32*	0.29*	0.28*	0.15*	0.10*	0.13*	-	-	-	-	-	-	-	-	-
Net Income	-125.8%	-1,226	4,745	-5,975	2,821	3,017	3,248	3,944	4,310	3,758	4,567	1,545	3,179	-2,094	2,941	3,002	3,219	2,357	1,901	2,670	2,915	1,827
Net Income Margin	-92.2%	0.01*	0.08*	0.05*	0.23*	0.24*	0.26*	0.29*	0.26*	0.27*	0.16*	0.13*	0.17*	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-743	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.0%	106,675	106,727	104,469	107,796	109,160	107,081	107,095	106,668	105,694	93,494	90,688	90,847	91,588	89,800	90,615	84,913	84,397	83,331	83,965	82,354	82,637
Current Assets	0.7%	32,168	31,954	29,977	33,402	35,722	33,561	32,116	31,184	30,266	31,058	28,665	26,909	27,764	26,577	29,343	26,174	27,483	26,142	24,298	25,351	25,875
Cash Equivalents	-20.5%	6,841	8,605	5,660	9,707	12,694	11,279	9,753	8,614	8,167	10,046	8,630	6,882	8,153	7,401	11,147	7,460	9,934	7,871	6,660	8,077	7,967
Inventory	3.7%	6,358	6,131	5,930	5,863	5,911	5,614	5,535	5,774	5,953	5,603	5,499	6,402	5,554	6,128	6,056	5,846	5,978	5,855	5,847	5,712	5,440
Net PPE	2.3%	23,051	22,526	22,231	21,758	21,422	20,424	20,059	19,747	19,279	18,565	18,064	18,295	17,000	16,919	15,789	15,269	14,297	14,287	13,862	13,506	13,291
Goodwill	0.1%	21,197	21,183	21,195	21,209	21,204	21,160	21,213	21,258	21,264	18,862	18,873	20,212	18,882	20,248	239	19,767	18,069	19,480	19,490	1,376	18,253
Current Liabilities	11.3%	25,694	23,094	23,394	23,131	24,239	22,998	23,168	22,316	23,872	23,728	21,906	26,361	27,327	20,405	22,178	23,483	22,220	20,684	20,085	18,543	22,206
Long Term Debt	-0.9%	33,683	33,972	34,072	28,074	28,745	28,482	28,684	30,586	30,690	22,907	24,033	24,002	25,360	26,321	26,156	21,637	22,736	22,677	22,771	22,721	19,806
LT Debt, Non Current	-0.9%	33,683	33,972	34,072	28,074	28,745	28,482	28,684	30,586	30,690	22,907	24,033	24,002	25,360	26,321	26,156	21,637	22,736	22,677	22,771	22,721	19,806
Shareholder's Equity	-8.9%	37,581	41,246	38,742	46,905	45,991	44,524	43,318	40,953	38,257	35,863	33,388	27,039	25,404	29,270	27,744	26,300	26,001	26,925	27,737	27,670	26,882
Retained Earnings	-5.6%	53,895	57,082	54,198	62,039	61,081	59,928	58,437	56,252	53,696	51,691	48,777	48,888	47,362	51,107	49,724	48,272	46,602	45,804	45,295	44,065	42,579
Additional Paid-In Capital	0.3%	44,509	44,358	44,219	44,467	44,379	44,243	44,115	44,275	44,238	44,149	44,039	39,613	39,588	39,489	39,373	39,697	39,660	39,561	39,484	38,768	38,808
Accumulated Depreciation	-1.0%	18,266	18,446	18,432	18,256	17,985	17,921	17,798	18,498	18,192	18,155	18,236	18,732	18,162	18,572	18,182	17,706	17,686	17,281	17,049	16,623	16,324
Minority Interest	0%	54.00	54.00	49.00	71.00	67.00	66.00	75.00	70.00	73.00	69.00	94.00	94.00	87.00	84.00	102	95.00	94.00	87.00	102	131	181
Float	-	-	-	292,929	-	-	-	230,820	-	-	-	196,870	-	-	-	195,461	-	-	-	215,106	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-96.8%	246	7,717	3,704	1,339	4,430	5,602	4,302	4,761	5,095	4,797	1,990	1,240	3,410	1,582	1,918	707	238	4,226	3,084	1,336	3,592
Share Based Compensation	1.8%	167	164	169	145	145	139	137	120	119	117	132	111	99.00	126	121	108	83.00	101	111	93.00	87.00
Cashflow From Investing	115.9%	53.00	-334	-11,443	-2,359	-1,748	-962	-1,077	-1,173	-12,049	-1,061	-2,625	-686	-4,697	-2,086	-782	-1,628	-663	191	-2,425	368	2,178
Cashflow From Financing	47.4%	-2,245	-4,269	3,758	-2,054	-1,554	-2,702	-1,777	-3,086	5,207	-2,274	2,262	-2,098	1,372	-3,851	1,137	-1,490	-2,011	-3,152	-2,084	-1,614	-5,566
Dividend Payments	-0.2%	1,852	1,855	1,885	1,853	1,750	1,747	1,770	1,745	1,643	1,649	1,673	1,645	1,542	1,545	1,577	1,551	1,405	1,394	1,468	1,428	1,277
Buy Backs	-15.7%	393	466	338	149	-	-	-	-	18.00	583	239	-	-	-	-	1,281	1,050	1,405	1,235	1,090	5,933

MRK Income Statement

2023-12-31

Consolidated Statement of (Loss) Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Sales	$ 60,115	$ 59,283	$ 48,704
Costs, Expenses and Other
Cost of sales	16,126	17,411	13,626
Selling, general and administrative	10,504	10,042	9,634
Research and development	30,531	13,548	12,245
Restructuring costs	599	337	661
Other (income) expense, net	466	1,501	(1,341)
Total costs, expenses and other	58,226	42,839	34,825
Income from Continuing Operations Before Taxes	1,889	16,444	13,879
Taxes on Income from Continuing Operations	1,512	1,918	1,521
Net Income from Continuing Operations	377	14,526	12,358
Less: Net Income Attributable to Noncontrolling Interests	12	7	13
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	365	14,519	12,345
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	0	0	704
Net Income Attributable to Merck & Co., Inc.	$ 365	$ 14,519	$ 13,049
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations (in dollars per share)	$ 0.14	$ 5.73	$ 4.88
Income from Discontinued Operations (in dollars per share)	0	0	0.28
Net Income (in dollars per share)	0.14	5.73	5.16
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations (in dollars per share)	0.14	5.71	4.86
Income from Discontinued Operations (in dollars per share)	0	0	0.28
Net Income (in dollars per share)	$ 0.14	$ 5.71	$ 5.14

MRK Balance Sheet

2023-12-31

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 6,841	$ 12,694
Short-term investments	252	498
Accounts receivable (net of allowance for doubtful accounts of $88 in 2023 and $72 in 2022)	10,349	9,450
Inventories (excludes inventories of $3,348 in 2023 and $2,938 in 2022 classified in Other assets - see Note 8)	6,358	5,911
Other current assets	8,368	7,169
Total current assets	32,168	35,722
Investments	252	1,015
Property, Plant and Equipment (at cost)
Land	326	295
Buildings	14,966	13,166
Machinery, equipment and office furnishings	17,763	16,760
Construction in progress	8,262	9,186
Property, plant and equipment (at cost)	41,317	39,407
Less: accumulated depreciation	18,266	17,985
Property, plant and equipment, net	23,051	21,422
Goodwill	21,197	21,204
Other Intangibles, Net	18,011	20,269
Other Assets	11,996	9,528
Total Assets	106,675	109,160
Current Liabilities
Loans payable and current portion of long-term debt	1,372	1,946
Trade accounts payable	3,922	4,264
Accrued and other current liabilities	15,766	14,159
Income taxes payable	2,649	1,986
Dividends payable	1,985	1,884
Total current liabilities	25,694	24,239
Long-Term Debt	33,683	28,745
Deferred Income Taxes	871	1,795
Other Noncurrent Liabilities	8,792	8,323
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	1,788	1,788
Other paid-in capital	44,509	44,379
Retained earnings	53,895	61,081
Accumulated other comprehensive loss	(5,161)	(4,768)
Stockholders' equity before deduction for treasury stock	95,031	102,480
Less treasury stock, at cost: 1,045,470,249 shares in 2023 and 1,039,269,638 shares in 2022	57,450	56,489
Total Merck & Co., Inc. stockholders’ equity	37,581	45,991
Noncontrolling Interests	54	67
Total equity	37,635	46,058
Total Liabilities and Equity	$ 106,675	$ 109,160

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

CEO	Mr. Robert M. Davis J.D.
WEBSITE	merck.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Merck & Co Inc Frequently Asked Questions

What is the ticker symbol for Merck & Co Inc? What does MRK stand for in stocks?

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merck & Co Inc (MRK)?

As of Wed Apr 17 2024, market cap of Merck & Co Inc is 317.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers. The fair value of Merck & Co Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merck & Co Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merck & Co Inc a good stock to buy?

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

What is Merck & Co Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, MRK's PE ratio (Price to Earnings) is 870.05 and Price to Sales (PS) ratio is 5.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merck & Co Inc's stock?

In the past 10 years, Merck & Co Inc has provided 0.119 (multiply by 100 for percentage) rate of return.